Presentation (CTI)

OBJECTIVES: This study aims to estimate the effectiveness of pertuzumab plus trastuzumab (dual-target therapy) vs trastuzumab alone (single targeted therapy) as the adjuvant treatment for Chinese patients with HER2-positive early breast cancer at high risk of recurrence, and analyze the long-term patient benefits of early breast cancer treatment.
METHODS: A six-state Markov model with monthly cycle was constructed over a lifetime horizon. Clinical data were observed from the Chinese high-risk subgroup (from Mainland China, Hong Kong, and Taiwan) in the APHINITY trial. The transition probabilities from invasive Disease Free Survival state to other states were estimated using a log-normal distribution, and transition probabilities between recurrence states were calculated based on advance cancer studies (i.e. CLEOPATRA and EMILIA clinical trial). Direct medical costs were obtained through a combination of expert opinions and real-world data, while indirect costs were calculated using expert opinions and national statistical data to estimate the labor productivity losses for patients and their families.
RESULTS: Dual-target therapy showed a 10-year recurrence rate reduction of 11.0% and a 10-year mortality rate reduction of 6.2% compared to single targeted therapy. By reducing the recurrence rate of early-stage breast cancer, the use of dual-target therapy resulted in an average cost-saving of CNY 59,661 in direct medical costs and CNY 8,993 in indirect costs per patient for advance cancer.
CONCLUSIONS: Breast cancer is a curable disease, and early standard treatment can significantly reduce the probability of disease progression, maximizing patients' health benefits. Moreover, early standard treatment can effectively reduce the direct medical costs and indirect costs caused by disease recurrence. The better the effectiveness of early-stage treatment regimens, the greater the long-term health benefits and cost savings for patients.